This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The fission product mixture contains significant amounts of molybdenum. Molybdenum-99 is of enormous interest to nuclear medicine as the parent nuclide to 99mTc, but its short half-life means it will usually decay long before the spent fuel is reprocessed. 99Mo can be produced both by fission followed by immediate reprocessing (usually only done in small-scale research reactors) or in particle accelerators. As molybdenum-100 only decays extremely slowly via double beta decay (half-life longer than the age of the universe), the molybdenum content of spent fuel will be essentially stable after a few days have passed to allow the molybdenum-99 to decay.
1 by the Minister, after consultation with such bodies representative of those interests as he may think fit, to represent the interests of persons using bicycles and tricycles, not being motor vehicles, within the London Traffic Area. † An A Licence entitled the holder to drive a motorcycle; a B Licence a motor car; and a C licence a heavy goods vehicle. The Committee and Traffic Area were abolished in 1965 by the London Government Act 1963.
In 2016, Burger King signed a build-to-suit lease agreement on a new 150,000 square feet (14,000 m2) five-story headquarters building to be built at 5707 Blue Lagoon Drive, just down the street from its existing nine-story headquarters at 5505 Blue Lagoon Drive. This was slightly smaller than the 200,000 square feet (19,000 m2) it was leasing in its current headquarters building at the time. In 2018, Burger King moved into its new headquarters at 5707 Blue Lagoon Drive. As of August 2024, the Burger King system operates more than 18,700 locations in more than 100 countries and U.S. territories.
== Signs and symptoms == The characteristic symptom of fibromyalgia is chronic widespread pain. The current prevalent diagnosis method also requires an above-threshold severity score from among six other symptoms: fatigue, trouble thinking or remembering, waking up tired (unrefreshed), pain or cramps in the lower abdomen, depression, and headache. Many other symptoms can be present. The key symptoms of fibromyalgia often present concurrently, in varying severity, and are intertwined with and influence each other.
Sources: en.wikipedia.org
== Summary == Strauss, a novelist, recounts how his life was profoundly altered when a car he was driving struck and killed a high school classmate. She was on a bicycle that swerved in front of his car. Although it was determined Strauss could in no way have avoided the accident, the book details his attempts, over half his life, to come to terms with his feelings of responsibility.
=== Etymology === Lymph originates in the Classical Latin word lympha "water", which is also the source of the English word limpid. The spelling with y and ph was influenced by folk etymology with Greek νύμϕη (nýmphē) "nymph". The adjective used for the lymph-transporting system is lymphatic. The adjective used for the tissues where lymphocytes are formed is lymphoid. Lymphatic comes from the Latin word lymphaticus, meaning "connected to water."
== Prognosis == The prognosis after myocardial infarction varies greatly depending on the extent and location of the affected heart muscle, and the development and management of complications. Prognosis is worse with older age and social isolation. Anterior infarcts, persistent ventricular tachycardia or fibrillation, development of heart blocks, and left ventricular impairment are all associated with poorer prognosis. Without treatment, about a quarter of those affected by MI die within minutes and about forty percent within the first month. Morbidity and mortality from myocardial infarction has, however, improved over the years due to earlier and better treatment: in those who have a STEMI in the United States, between 5 and 6 percent die before leaving the hospital and 7 to 18 percent die within a year. It is unusual for babies to experience a myocardial infarction, but when they do, about half die. In the short-term, neonatal survivors seem to have a normal quality of life.
Sources: en.wikipedia.org
21 April – Mark Menzies quits the Conservative Party and says he will stand down from Parliament at the next election. Robin Swann, who is the perspective Ulster Unionist candidate for South Antrim, announces he will step down from his post as Northern Ireland's Health Minister once the general election campaign begins. 22 April – Parliament passes the Safety of Rwanda Bill, with plans to deport the first asylum seekers to Kigali in July. Two men, including a parliamentary researcher, are charged with spying for China after providing information that could be "useful to an enemy". Conservative councillor Richard Solesbury-Timms, who represents Middleton Cheney on West Northamptonshire Council, leaves the party to sit as an independent citing the party's dealing with allegations against the council leader. 23 April – Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. Alliance Party MLA Patrick Brown resigns his South Down seat in the Northern Ireland Assembly, citing personal reasons for doing so. 24 April – Rishi Sunak vows to increase UK defence spending to 2.5% of GDP by 2030. Labour unveils its plans for improvements to train services, which include automatic refunds for delays, a "best price" guarantee and improved internet coverage. Jeffrey Donaldson appears at Newry Magistrates' Court to face charges of historic child abuse. Johnny Timpson, the UK's inaugural disability ambassador, resigns over the UK government's policy of clawing back benefit overpayment.
The oral bioavailability of acetylcysteine is relatively low due to extensive first-pass metabolism in the gut wall and liver. It ranges between 6% and 10%. Intravenous administration of acetylcysteine bypasses the first-pass metabolism, resulting in higher bioavailability compared to oral administration. Intravenous administration of acetylcysteine ensures nearly 100% bioavailability as it directly enters the bloodstream. Acetylcysteine is extensively liver metabolized, CYP450 minimal. After a single IV administration, urine excretion is 30% at 0.11 L/hr/kg, with a half-life of 5.6 hours. Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals. Nitroglycerin interacts moderately with NAC, possibly resulting in hypotension and nitroglycerin-induced headache. Intravenous NAC can cause rate-related anaphylactoid reaction, usually mild.
In the molecule lawrencium dihydride (LrH2), which is predicted to be bent, the 6d orbital of lawrencium is not expected to play a role in the bonding, unlike that of lanthanum dihydride (LaH2). LaH2 has La–H bond distances of 2.158 Å, while LrH2 should have shorter Lr–H bond distances of 2.042 Å due to the relativistic contraction and stabilization of the 7s and 7p orbitals involved in the bonding, in contrast to the core-like 5f subshell and the mostly uninvolved 6d subshell. In general, molecular LrH2 and LrH are expected to resemble the corresponding thallium species (thallium having a 6s26p1 valence configuration in the gas phase, like lawrencium's 7s27p1) more than the corresponding lanthanide species. The electron configurations of Lr+ and Lr2+ are expected to be 7s2 and 7s1 respectively. However, in species where all three valence electrons of lawrencium are ionized to give at least formally the Lr3+ cation, lawrencium is expected to behave like a typical actinide and the heavier congener of lutetium, especially because the first three ionization potentials of lawrencium are predicted to be similar to those of lutetium. Hence, unlike thallium but like lutetium, lawrencium would prefer to form LrH3 than LrH, and LrCO is expected to be similar to the also unknown LuCO, both metals having valence configuration σ2π1 in their monocarbonyls. The pπ–dπ bond is expected to be seen in LrCl3 just as it is for LuCl3 and more generally all the LnCl3.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.